Published in J Exp Med on September 16, 2002
TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev (2008) 4.85
The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J (2005) 2.38
p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev (2004) 2.07
Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev (2010) 2.06
Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol (2004) 2.01
TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J (2005) 1.90
Tissue-specific alternative splicing of TCF7L2. Hum Mol Genet (2009) 1.80
DeltaNp73beta is active in transactivation and growth suppression. Mol Cell Biol (2004) 1.56
Wnt activation and alternative promoter repression of LEF1 in colon cancer. Mol Cell Biol (2006) 1.48
p63 and p73 transcriptionally regulate genes involved in DNA repair. PLoS Genet (2009) 1.41
Potential role for p53 in the permissive life cycle of human cytomegalovirus. J Virol (2006) 1.40
A gene signature-based approach identifies mTOR as a regulator of p73. Mol Cell Biol (2008) 1.34
deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol (2003) 1.33
p73 in Cancer. Genes Cancer (2011) 1.33
Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions. Cancer (2008) 1.32
Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat (2008) 1.32
p53 Family: Role of Protein Isoforms in Human Cancer. J Nucleic Acids (2011) 1.26
Skin human papillomavirus type 38 alters p53 functions by accumulation of deltaNp73. EMBO Rep (2006) 1.24
p73 deficiency results in impaired self renewal and premature neuronal differentiation of mouse neural progenitors independently of p53. Cell Death Dis (2010) 1.20
Multiple novel nesprin-1 and nesprin-2 variants act as versatile tissue-specific intracellular scaffolds. PLoS One (2012) 1.17
Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems. Diagn Pathol (2012) 1.14
Regulation of p73 activity by post-translational modifications. Cell Death Dis (2012) 1.12
p73 expression is regulated by RNPC1, a target of the p53 family, via mRNA stability. Mol Cell Biol (2012) 1.10
The antiapoptotic DeltaNp73 is degraded in a c-Jun-dependent manner upon genotoxic stress through the antizyme-mediated pathway. Proc Natl Acad Sci U S A (2010) 1.09
Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2. Proc Natl Acad Sci U S A (2010) 1.08
Antisense gapmers selectively suppress individual oncogenic p73 splice isoforms and inhibit tumor growth in vivo. Mol Cancer (2009) 1.06
DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function. Oncogene (2007) 1.06
Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. J Cell Mol Med (2009) 1.06
Overexpressed TP73 induces apoptosis in medulloblastoma. BMC Cancer (2007) 1.05
Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia (2006) 1.05
Multiple stress signals induce p73beta accumulation. Neoplasia (2004) 1.05
Diverse p63 and p73 isoforms regulate Δ133p53 expression through modulation of the internal TP53 promoter activity. Cell Death Differ (2011) 1.03
p53: the attractive tumor suppressor in the cancer research field. J Biomed Biotechnol (2010) 1.02
An isoform of ZBP-89 predisposes the colon to colitis. Nucleic Acids Res (2006) 1.02
p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO J (2008) 1.01
U-box-type ubiquitin E4 ligase, UFD2a attenuates cisplatin mediated degradation of DeltaNp63alpha. Cell Cycle (2008) 1.00
The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation. J Biol Chem (2011) 0.99
p73 protein regulates DNA damage repair. FASEB J (2011) 0.96
Regulatory feedback loop between TP73 and TRIM32. Cell Death Dis (2013) 0.95
CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood (2006) 0.95
Analysis of the oligomeric state and transactivation potential of TAp73α. Cell Death Differ (2013) 0.94
Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. Mol Cancer Ther (2010) 0.94
p73 Is Required for Multiciliogenesis and Regulates the Foxj1-Associated Gene Network. Cell Rep (2016) 0.93
Specific isoforms of p73 control the induction of cell death induced by the viral proteins, E1A or apoptin. Cell Cycle (2007) 0.93
p73 is required for endothelial cell differentiation, migration and the formation of vascular networks regulating VEGF and TGFβ signaling. Cell Death Differ (2015) 0.93
Transcriptional regulation of the p73 gene by Nrf-2 and promoter CpG methylation in human breast cancer. Oncotarget (2014) 0.91
p73 plays a role in erythroid differentiation through GATA1 induction. J Biol Chem (2009) 0.91
p73 as a pharmaceutical target for cancer therapy. Curr Pharm Des (2011) 0.90
Crosstalk between c-Jun and TAp73alpha/beta contributes to the apoptosis-survival balance. Nucleic Acids Res (2011) 0.90
Gain of cellular adaptation due to prolonged p53 impairment leads to functional switchover from p53 to p73 during DNA damage in acute myeloid leukemia cells. J Biol Chem (2010) 0.89
IkappaB kinase beta promotes cell survival by antagonizing p53 functions through DeltaNp73alpha phosphorylation and stabilization. Mol Cell Biol (2011) 0.89
Molecular basis of the interactions between the p73 N terminus and p300: effects on transactivation and modulation by phosphorylation. Proc Natl Acad Sci U S A (2009) 0.89
DeltaNp73 modulates nerve growth factor-mediated neuronal differentiation through repression of TrkA. Mol Cell Biol (2007) 0.88
Eukaryotic translation elongation factor 1-alpha 1 inhibits p53 and p73 dependent apoptosis and chemotherapy sensitivity. PLoS One (2013) 0.87
Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73 abundance: mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs. Cell Death Differ (2014) 0.87
Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J Clin Pathol (2005) 0.86
Cataloging and organizing p73 interactions in cell cycle arrest and apoptosis. Nucleic Acids Res (2008) 0.86
Structure and apoptotic function of p73. BMB Rep (2015) 0.85
The interaction between C35 and ΔNp73 promotes chemo-resistance in ovarian cancer cells. Br J Cancer (2013) 0.85
Novel therapeutic interventions for p53-altered tumors through manipulation of its family members, p63 and p73. Cell Cycle (2016) 0.85
Regulation of ΔNp63α by NFκΒ. Cell Cycle (2010) 0.85
Loss of the Gata1 gene IE exon leads to variant transcript expression and the production of a GATA1 protein lacking the N-terminal domain. J Biol Chem (2009) 0.84
PUMA Cooperates with p21 to Regulate Mammary Epithelial Morphogenesis and Epithelial-To-Mesenchymal Transition. PLoS One (2013) 0.84
A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression. Oncogene (2014) 0.83
Mechanisms, function and clinical applications of DNp73. Cell Cycle (2013) 0.83
p63 and p73 expression in extrahepatic bile duct carcinoma and their clinical significance. J Mol Histol (2007) 0.83
TAp73-mediated the activation of c-Jun N-terminal kinase enhances cellular chemosensitivity to cisplatin in ovarian cancer cells. PLoS One (2012) 0.83
Epstein - Barr virus transforming protein LMP-1 alters B cells gene expression by promoting accumulation of the oncoprotein ΔNp73α. PLoS Pathog (2013) 0.83
Relative expression of TAp73 and ΔNp73 isoforms. Aging (Albany NY) (2012) 0.82
p73 expression is regulated by ribosomal protein RPL26 through mRNA translation and protein stability. Oncotarget (2016) 0.82
p63 regulates cell proliferation and cell cycle progression‑associated genes in stromal cells of giant cell tumor of the bone. Int J Oncol (2012) 0.81
Induction of the small heat shock protein alphaB-crystallin by genotoxic stress is mediated by p53 and p73. Breast Cancer Res Treat (2009) 0.81
Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors. Oncotarget (2015) 0.80
Interplay between TAp73 Protein and Selected Activator Protein-1 (AP-1) Family Members Promotes AP-1 Target Gene Activation and Cellular Growth. J Biol Chem (2015) 0.80
Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma. Neuro Oncol (2015) 0.79
Crocetin exploits p53-induced death domain (PIDD) and FAS-associated death domain (FADD) proteins to induce apoptosis in colorectal cancer. Sci Rep (2016) 0.78
p73-Binding Partners and Their Functional Significance. Int J Proteomics (2011) 0.78
Role of p73 Dinucleotide Polymorphism in Prostate Cancer and p73 Protein Isoform Balance. Prostate Cancer (2014) 0.78
Differential expression of p53, p63 and p73 protein and mRNA for DMBA-induced hamster buccal-pouch squamous-cell carcinomas. Int J Exp Pathol (2004) 0.78
TAp73 transcriptionally represses BNIP3 expression. Cell Cycle (2015) 0.77
WWP2-WWP1 ubiquitin ligase complex coordinated by PPM1G maintains the balance between cellular p73 and ΔNp73 levels. Mol Cell Biol (2014) 0.77
Novel Implications of DNA Damage Response in Drug Resistance of Malignant Cancers Obtained from the Functional Interaction between p53 Family and RUNX2. Biomolecules (2015) 0.77
Two isoforms of HOXA9 function differently but work synergistically in human MLL-rearranged leukemia. Blood Cells Mol Dis (2012) 0.77
ΔNp73 enhances promoter activity of TGF-β induced genes. PLoS One (2012) 0.76
PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers. Oncogene (2009) 0.76
Analysis of the intracellular localization of p73 N-terminal protein isoforms TAp73 and ∆Np73 in medulloblastoma cell lines. J Mol Histol (2010) 0.76
The dominant-negative interplay between p53, p63 and p73: A family affair. Oncotarget (2016) 0.75
Nuclear localization of the caspase-3-cleaved form of p73 in anoikis. Oncotarget (2016) 0.75
UBE4B: a promising regulatory molecule in neuronal death and survival. Int J Mol Sci (2012) 0.75
Loss of LZAP inactivates p53 and regulates sensitivity of cells to DNA damage in a p53-dependent manner. Oncogenesis (2017) 0.75
miRNA-193a-5p repression of p73 controls Cisplatin chemoresistance in primary bone tumors. Oncotarget (2016) 0.75
ΔNp73 overexpression promotes resistance to apoptosis but does not cooperate with PML/RARA in the induction of an APL-leukemic phenotype. Oncotarget (2016) 0.75
∆Np73 is capable of inducing apoptosis by co-ordinately activating several BH3-only proteins. Biosci Rep (2015) 0.75
Role of p63 and p73 isoforms on the cell death in patients with hepatocellular carcinoma submitted to orthotopic liver transplantation. PLoS One (2017) 0.75
Surfing the p53 network. Nature (2000) 35.36
The p53 proto-oncogene can act as a suppressor of transformation. Cell (1989) 11.67
Suppression of human colorectal carcinoma cell growth by wild-type p53. Science (1990) 11.18
Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature (1993) 7.90
Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell (1997) 7.27
Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (1992) 6.73
p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature (2000) 5.83
p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature (1997) 5.42
The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature (1999) 5.33
E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell (1996) 5.26
p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol (1990) 5.20
Tumor surveillance via the ARF-p53 pathway. Genes Dev (1998) 5.11
Tumor induction and tissue atrophy in mice lacking E2F-1. Cell (1996) 4.80
AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci U S A (2000) 4.37
Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem (2000) 4.11
Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature (2000) 3.83
p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature (1999) 3.55
Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature (1999) 3.50
Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci U S A (1994) 3.36
An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science (2000) 3.12
Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet (2000) 3.03
p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J (1992) 2.90
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet (2000) 2.69
Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A (1995) 2.56
p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol (1999) 2.41
Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ (2001) 2.40
DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol Cell (2002) 2.29
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation. Nature (2000) 2.10
The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res (1998) 2.06
Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Res (2000) 1.80
Autoinhibitory regulation of p73 by Delta Np73 to modulate cell survival and death through a p73-specific target element within the Delta Np73 promoter. Mol Cell Biol (2002) 1.72
High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene (2000) 1.53
Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res (2002) 1.47
Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res (1999) 1.38
Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J Biol Chem (2002) 1.37
Oncogenes induce and activate endogenous p73 protein. J Biol Chem (2000) 1.34
Cytoplasmically sequestered wild-type p53 protein in neuroblastoma is relocated to the nucleus by a C-terminal peptide. Proc Natl Acad Sci U S A (1996) 1.31
Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ (1998) 1.17
Transactivation-deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene (2001) 1.15
p53, p63 and p73--solos, alliances and feuds among family members. Biochim Biophys Acta (2001) 1.15
Identification of a sequence element from p53 that signals for Mdm2-targeted degradation. Mol Cell Biol (2000) 1.14
Overexpression of the MDM2 oncogene in leukemia and lymphoma. Leuk Lymphoma (1996) 1.05
p73 cooperates with DNA damage agents to induce apoptosis in MCF7 cells in a p53-dependent manner. Oncogene (2001) 0.97
Analysis of p73 in human borderline and invasive ovarian tumor. Oncogene (2000) 0.92
p73 is over-expressed in vulval cancer principally as the Delta 2 isoform. Br J Cancer (2001) 0.84
p53 has a direct apoptogenic role at the mitochondria. Mol Cell (2003) 8.98
Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97
p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell (2012) 4.11
p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res (2008) 3.58
The mitochondrial p53 pathway. Biochim Biophys Acta (2008) 2.98
p63 and p73: roles in development and tumor formation. Mol Cancer Res (2004) 2.96
Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J (2007) 2.62
Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc Natl Acad Sci U S A (2007) 2.52
In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol (2004) 2.50
Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. Kidney Int (2011) 2.28
p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res (2008) 2.27
Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res (2006) 2.17
The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle (2009) 2.00
WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem (2006) 1.94
Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol (2010) 1.94
Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res (2011) 1.77
U.S. Food and Drug Administration's Guidance Regarding Morcellation of Leiomyomas: Well-Intentioned, But Is It Harmful for Women? Obstet Gynecol (2016) 1.70
p73 suppresses polyploidy and aneuploidy in the absence of functional p53. Mol Cell (2007) 1.41
Links between mutant p53 and genomic instability. J Cell Biochem (2012) 1.41
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res (2004) 1.36
Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage. FASEB J (2002) 1.34
deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol (2003) 1.33
Mitochondrially targeted p53 has tumor suppressor activities in vivo. Cancer Res (2005) 1.33
Acupuncture-point stimulation for chemotherapy-induced nausea and vomiting. J Clin Oncol (2005) 1.32
TP53 Mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer (2011) 1.30
Direct reprogramming by oncogenic Ras and Myc. Proc Natl Acad Sci U S A (2013) 1.26
The role of ubiquitination in the direct mitochondrial death program of p53. Cell Cycle (2007) 1.25
Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med (2012) 1.23
Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med (2007) 1.19
Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol Cell (2005) 1.17
Novel derivatives of benzo[b]thieno[2,3-c]quinolones: synthesis, photochemical synthesis, and antitumor evaluation. J Med Chem (2003) 1.15
Stress-induced p53 runs a transcription-independent death program. Biochem Biophys Res Commun (2005) 1.13
BclxL changes conformation upon binding to wild-type but not mutant p53 DNA binding domain. J Biol Chem (2009) 1.12
Detection of mitochondrial localization of p53. Methods Mol Biol (2003) 1.11
Synthesis, structural studies, and biological evaluation of some purine substituted 1-aminocyclopropane-1-carboxylic acids and 1-amino-1-hydroxymethylcyclopropanes. Nucleosides Nucleotides Nucleic Acids (2003) 1.07
CyberKnife Boost for Patients with Cervical Cancer Unable to Undergo Brachytherapy. Front Oncol (2012) 1.06
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res (2005) 1.05
Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage. FASEB J (2003) 1.04
Endogenous retrovirus drives hitherto unknown proapoptotic p63 isoforms in the male germ line of humans and great apes. Proc Natl Acad Sci U S A (2011) 1.03
Endometrial cancer: what is a clinician to do? Obstet Gynecol (2007) 1.01
Stress-induced p53 runs a direct mitochondrial death program: its role in physiologic and pathophysiologic stress responses in vivo. Cell Cycle (2004) 1.01
Impaired DNA damage checkpoint response in MIF-deficient mice. EMBO J (2007) 0.98
A randomized controlled trial of a regular diet as the first meal in gynecologic oncology patients undergoing intraabdominal surgery. Obstet Gynecol (2002) 0.97
A role of HAUSP in tumor suppression in a human colon carcinoma xenograft model. Cell Cycle (2008) 0.97
Macrophage migration inhibitory factor coordinates DNA damage response with the proteasomal control of the cell cycle. Cell Cycle (2007) 0.96
Mitochondrially targeted wild-type p53 induces apoptosis in a solid human tumor xenograft model. Cell Cycle (2008) 0.96
Ovaries, estrogen, and longevity. Obstet Gynecol (2013) 0.96
A high-grade uterine leiomyosarcoma with human chorionic gonadotropin production. Int J Gynecol Pathol (2006) 0.94
Efficient RNA interference depends on global context of the target sequence: quantitative analysis of silencing efficiency using Eulerian graph representation of siRNA. Nucleic Acids Res (2004) 0.94
Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer (2007) 0.94
Viral and cellular oncogenes induce rapid mitochondrial translocation of p53 in primary epithelial and endothelial cells early in apoptosis. FEBS Lett (2005) 0.93
p53 mutations as fingerprints for aristolochic acid: an environmental carcinogen in endemic (Balkan) nephropathy. Mutat Res (2009) 0.93
Role of the p53 family in stabilizing the genome and preventing polyploidization. Adv Exp Med Biol (2010) 0.91
Brdm2 - an aberrant hypomorphic p63 allele. Cell Death Differ (2010) 0.90
Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice. J Clin Invest (2010) 0.90
Mitochondrial p53 mediates a transcription-independent regulation of cell respiration and interacts with the mitochondrial F₁F0-ATP synthase. Cell Cycle (2013) 0.89
Activation of EDTA-resistant gelatinases in malignant human tumors. Cancer Res (2006) 0.88
"Malignant" uterine perivascular epithelioid cell tumor, pelvic lymph node lymphangioleiomyomatosis, and gynecological pecomatosis in a patient with tuberous sclerosis: a case report and review of the literature. Int J Gynecol Pathol (2008) 0.88
TAp73 is essential for germ cell adhesion and maturation in testis. J Cell Biol (2014) 0.86
Identification of p53 in mitochondria. Methods Mol Biol (2013) 0.85
Targeting the heat shock protein 90: a rational way to inhibit macrophage migration inhibitory factor function in cancer. Curr Opin Oncol (2014) 0.85
Role of p53 family members p73 and p63 in human hematological malignancies. Leuk Lymphoma (2012) 0.84
Primary extrauterine endometrial stromal cell sarcoma: a case and review. J Gastrointest Cancer (2009) 0.83
Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers. Int J Oncol (2006) 0.82
Promoting knowledge of cancer prevention and screening in an underserved Hispanic women population: a culturally sensitive education program. Health Promot Pract (2010) 0.82
Analysis of nuclear and cytoplasmic degradation of p53 in cells after stress. Methods Mol Biol (2003) 0.81
Cortical hypoplasia and ventriculomegaly of p73-deficient mice: Developmental and adult analysis. J Comp Neurol (2014) 0.80
Mutational analysis of p53 in human tumors: direct DNA sequencing and SSCP. Methods Mol Biol (2003) 0.80
E2F1 plays a direct role in Rb stabilization and p53-independent tumor suppression. Cell Cycle (2008) 0.80
Comparison of tolerance of combination carboplatin and paclitaxel chemotherapy by age in women with ovarian cancer. Gynecol Oncol (2002) 0.80
Carcinomas of ovary and lung with clear cell features: can immunohistochemistry help in differential diagnosis? Int J Gynecol Pathol (2007) 0.80
Reduced telomere length is not associated with early signs of vascular aging in young men born after intrauterine growth restriction: a paradox? J Hypertens (2014) 0.80
Outcomes and Postoperative Complications After Hysterectomies Performed for Benign Compared With Malignant Indications. Obstet Gynecol (2016) 0.79
Mutational analysis of p53 in human tumors: immunocytochemistry. Methods Mol Biol (2003) 0.79
HSP90 inhibitor antagonizing MIF: The specifics of pleiotropic cancer drug candidates. Oncoimmunology (2012) 0.78
WITHDRAWN: Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting. Cochrane Database Syst Rev (2014) 0.78
Osteopontin traffic in hypoxic renal epithelial cells. Nephron Exp Nephrol (2003) 0.78
Outcomes of endometrial cancer patients undergoing surgery with gynecologic oncology involvement. Obstet Gynecol (2002) 0.77
Generation of p53-deficient induced pluripotent stem cells from mouse embryo fibroblasts. Methods Mol Biol (2013) 0.77
Heavier workload, less personal control: Impact of delivery on obstetrician/gynecologists' career satisfaction. Am J Obstet Gynecol (2004) 0.77
Pilot phase 2 trial of 4 months of maintenance pegylated liposomal Doxorubicin in patients with advanced ovarian cancer after complete response to platinum and Paclitaxel-based chemotherapy. Gynecol Obstet Invest (2006) 0.77
Differential effects of diverse p53 isoforms on TAp73 transcriptional activity and apoptosis. Carcinogenesis (2012) 0.77
Synthesis, photochemical synthesis and antitumor evaluation of novel derivatives of thieno[3',2':4,5]thieno[2,3-c]quinolones. Chem Pharm Bull (Tokyo) (2002) 0.77
p63 and canonical Wnt signaling. Cell Cycle (2010) 0.77
NSQIP--the new frontier? Gynecol Oncol (2008) 0.76
p63 regulation by microRNAs. Cell Cycle (2009) 0.76
Rational design of DNA sequences for nanotechnology, microarrays and molecular computers using Eulerian graphs. Nucleic Acids Res (2004) 0.76
Optimising treatment of elderly patients with ovarian cancer : improving their enrollment in clinical trials. Drugs Aging (2005) 0.76
p53 further extends its reach. Oncoimmunology (2013) 0.75
A randomized controlled trial of early oral analgesia in gynecologic oncology patients undergoing intra-abdominal surgery. Obstet Gynecol (2002) 0.75
Gynecologic oncology quality measures: what really matters? Gynecol Oncol (2013) 0.75
New membership model. Gynecol Oncol (2009) 0.75
Self Reported Quality of Life Among Patients Who Have Undergone Outpatient IP Chemotherapy for Ovarian Cancer [11]. Obstet Gynecol (2016) 0.75
Sertoliform endometrioid carcinoma of the endometrium with dual immunophenotypes for epithelial membrane antigen and inhibin alpha: case report and literature review. Int J Gynecol Pathol (2007) 0.75